STRADEFY BIOSCIENCES

STRADEFY BIOSCIENCESSTRADEFY BIOSCIENCESSTRADEFY BIOSCIENCES

Pioneering next-generation Bioadhesive Drug Carriers (BDCs)

OUR MISSION

Stradefy Biosciences is pioneering next-generation bioadhesive drug carriers (BDCs), rationally engineered for cellular bioadhesion, uptake and therapeutic payload release, at levels well beyond seen with antibody drug conjugates (ADCs). Lead candidates, initially targeting unmet needs in the oncology and immunology areas, have demonstrated in vivo proof of efficacy and are advancing to the IND stage. 


Based in New Haven, CT, Stradefy was co-founded by Mark Saltzman, Michael Girardi, Yale University and Elm Street Ventures.

BDC'S

STRATEGY

STRATEGY

BDC's maximize the efficacy of active drug product by optimizing retention and internalization in target tissues and cells. They are analogous to ADCs with higher active drug loads and differentiated retention and cell internalization.


STRATEGY

STRATEGY

STRATEGY

    Our lead candidate has demonstrated efficacy in multiple oncology models. We have a capital efficient path to obtain proof of concept in targeted oncology.


RESEARCH

STRATEGY

RESEARCH

Stradefy is based on the research of Mark Saltzman and Mike Girardi at Yale University, and has strong patent protection. 


LEADERSHIP

Mark Saltzman, Ph.D

Jeffrey Goldberg, MS, MBA

Michael Girardi, M.D.

Academic Founder


Goizueta Foundation

Professor of Chemical and Biomedical Engineering

Yale University


Michael Girardi, M.D.

Jeffrey Goldberg, MS, MBA

Michael Girardi, M.D.

Academic Founder


Vice Chair & Evans Prof of Dermatology

Yale School of Medicine

Jeffrey Goldberg, MS, MBA

Jeffrey Goldberg, MS, MBA

Jeffrey Goldberg, MS, MBA

Executive Chair

Jeff Goldberg is Executive Chair of Stradefy Biosciences and an advisor to several other therapeutics companies.  Previously, he served as CEO of Aeglea

BioTherapeutics, CEO of Immunitas Therapeutics, and COO of Akcea Therapeutics. 

Brian Dixon, Ph.D.

Jeffrey Goldberg, MS, MBA

Jeffrey Goldberg, MS, MBA

Venture Partner

Brian is a Venture Partner at  Elm Street Ventures.  Prior to ESV he was CEO of BioRelix, Inc., and prior to that he directed drug discovery, DPMK, and other key R&D activities at Bayer. 


CONTACT US

If you are interested in learning more about our work, we'd love to hear from you. Please contact Jeff Goldberg, Executive Chair, at the form below.

Get In Touch

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Stradefy Biosciences

Copyright © 2025 Stradefy Biosciences - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept